Announced Wed, 8 Jul · 18:20 IST
RTA certificate on dematerialisation for June 2026 quarter
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.1%1-day move
₹2600.00
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+0.1+5.3+10.8+8.0-61.7-63.5————
Up moveDown movePending
AI summary
Fredun Pharmaceuticals submitted a routine compliance certificate under SEBI Regulation 74(5) for the quarter ended June 30, 2026. The certificate from their Registrar and Share Transfer Agent, Purva Sharegistry, confirms processing of dematerialisation requests received during the month. The filing notes that no shares were dematerialised in June 2026. This is a standard procedural filing required every quarter.
Likely market impact
Routine regulatory compliance filing with no material impact on business or shareholders. No shares were dematerialised during the month.